The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.smaller Cos. Regulatory News (BSV)

Share Price Information for Br.smaller Cos. (BSV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 80.00
Bid: 78.50
Ask: 81.50
Change: 0.00 (0.00%)
Spread: 3.00 (3.822%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 80.00
BSV Live PriceLast checked at -
British Smaller Companies VCT is an Investment Trust

To maximise Total Return and provide investors with an attractive long-term tax-free dividend yield while maintaining the Company's status as a venture capital trust.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

1st Quarter Results

10 Sep 2021 15:24

RNS Number : 4580L
British Smaller Companies VCT PLC
10 September 2021
 

British Smaller Companies VCT plc

Interim Management Statement

For the quarter ended 30 June 2021

British Smaller Companies VCT plc (the "Company") presents its interim management statement for the quarter ended 30 June 2021. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

As announced on 27 August 2021, the Company's Total Return at 30 June 2021 was 245.6 pence per ordinary share, representing an increase of 12.4 pence per ordinary share over the Total Return of 233.2 pence per ordinary share as at 31 March 2021. The increase represents 16.4 per cent of the opening net asset value of 75.8 pence per share.

Five follow-on investments totalling £3.4 million were made during the quarter.

The Company completed the sale of its shareholding in Deep-Secure Ltd in July. The exit (which was realised at the value held at 30 June 2021) generated capital proceeds of £6.6 million delivering a profit of £5.6 million above cost, and an uplift of £2.4 million on the carrying value at the beginning of the financial year. Including income, the total return from this investment was £7.7 million over an 11.6 year holding period, producing an internal rate of return of 23 per cent and a multiple of 7.7x cost.

On 27 August 2021 the Company also announced that contracts had been exchanged for the partial sale of its holding in Matillion, with completion expected 30 days from the exchange of contracts. The impact following this exchange of contracts is an additional increase on the 30 June 2021 Net Asset Value of 1.8 pence per ordinary share, (equivalent to 2.0 per cent).

Performance

The movement in Total Return in pence per ordinary share is set out in the table below:

31 March 2021

Increase in Value

Buyback of shares

Movement

In Period

30 June 2021

Net Assets (£m)

110.4

18.0

(0.6)

17.4

127.8

NAV per share (PPS)

75.8p

12.4p

-

12.4p

88.2

Cumulative dividends paid (PPS)

157.4p

-

-

-

157.4p

Total Return (PPS)

233.2p

12.4p

-

12.4p

245.6p

Shares in issue

145,624,667

-

(781,869)

(781,869)

144,842,798

The unaudited NAV per ordinary share increased from 75.8 pence per share to 88.2 pence per share, equivalent to 16.4 per cent in the period. Cumulative dividends paid at 30 June 2021 were 157.4 pence per ordinary share (31 March 2021: 157.4 pence per ordinary share).

The movements in NAV per ordinary share are set out in the table below:

 

 

£m

Pence per

ordinary share

NAV at 31 March 2021

110.4

75.8

Increase in portfolio value

18.3

12.6

Net operating costs

(0.3)

(0.2)

Issue/buy-back of shares

(0.6)

-

17.4

12.4

NAV at 30 June 2021

127.8

88.2

 

Following payment of the interim dividend of 2.0 pence per ordinary share for the year ending 31 March 2022 on 23 July 2021 the unaudited net asset value is 86.2 pence per ordinary share.

Dividends and shares in issue

On 24 June 2021 the Company purchased 781,869 ordinary shares of 10 pence each at a price of 70.61 pence per ordinary share. These shares were placed in treasury.

The number of ordinary shares in issue at 30 June 2021 was 144,842,798 (31 March 2021: 145,624,667). In addition, at 30 June 2021 the Company held 16,468,050 ordinary shares in treasury (31 March 2021: 15,686,181).

Following the payment of the interim dividend of 2.0 pence per share the Company issued 1,022,316 ordinary shares under the DRIS, taking the number of ordinary shares in issue to 145,865,114 at that date.

Net assets

Net assets at 30 June 2021 comprised the following:

£000

% of net assets

Unquoted investments at fair value

95,398

74.7

Listed investment funds

4,980

3.9

Cash and cash equivalents

26,573

20.8

Other net current assets

814

0.6

Net assets

127,765

100.0

 

Investments

The investment portfolio at 30 June 2021 comprised:

Valuation

£000

Valuation as a % of net assets

Matillion Limited

30,171

23.6%

Deep-Secure Ltd

6,551

28.7%

Intelligent Office UK

4,585

32.3%

Wooshii Limited

4,277

35.7%

Springboard Research Holdings Limited

4,257

39.0%

Unbiased EC1 Limited

4,027

42.2%

SharpCloud Software Limited

4,007

45.3%

Elucidat Ltd

3,970

48.4%

Force24 Ltd

3,409

51.1%

ACC Aviation Group Limited

3,315

53.7%

Displayplan Holdings Limited

2,925

56.0%

KeTech Enterprises Limited

2,748

58.2%

Arcus Global Limited

2,599

60.2%

Ncam Technologies Limited

2,394

62.1%

Sipsynergy

(via Hosted Network Services Limited)

1,745

63.5%

Tonkotsu Limited

1,739

64.9%

Vypr Validation Technologies Limited

1,681

66.2%

Arraco Global Markets Limited

1,676

67.5%

Outpost VFX Limited

1,676

68.8%

Frescobol Carioca Ltd

1,296

69.7%

89,048

69.7%

Other investments

6,350

5.0%

Total investments

95,398

74.7%

Investments made since November 2015 represented 71 per cent of the value of the unquoted portfolio at 30 June 2021.

Portfolio performance

Over the quarter to 30 June 2021 the aggregate portfolio valuation has increased by £18.3 million which incorporates a number of increased valuations including Matillion (£14.5m) and Deep Secure (£2.4m).

Fundraising

It is anticipated that the Company's proposed Joint Fundraising with British Smaller Companies VCT2 plc in the 2021/22 tax year will open in the week commencing 20 September 2021, seeking to raise in aggregate £40 million, with an over-allotment facility of £20 million. Further details of the Fundraising will be announced at the time of the launch.

Investment Policy

The investment policy of the Company is to invest in UK businesses across a broad range of sectors that blends a mix of businesses operating in established and emerging industries that offer opportunities in the application and development of innovation in their products and services.

These investments will all meet the definition of a Qualifying Investment and be primarily in unquoted UK companies. It is anticipated that the majority of these will be re-investing their profits for growth and the investments will, therefore, comprise mainly equity instruments.

The Company seeks to build a broad portfolio of investments in early stage companies focused on growth with the aim of spreading the maturity profiles and maximising return as well as ensuring compliance with the VCT guidelines in this regard.

Borrowing

The Company funds the investment programmes out of its own resources and has no borrowing facilities for this purpose.

Co-investment

British Smaller Companies VCT plc and British Smaller Companies VCT2 plc ("the VCTS") have in aggregate first choice of all investment opportunities meeting the VCT qualifying criteria that require up to £4.5 million of equity. Amounts above £4.5 million will be allocated one third to YFM's co-investment funds and two thirds to the VCTs. Where there are opportunities for the VCTs to co-invest with each other the basis for allocation is 60 per cent to the Company and 40 per cent to British Smaller Companies VCT2 plc. The Board of the Company has discretion as to whether or not to take up or, where British Smaller Companies VCT2 plc does not take up its allocation, increase its allocation in such co-investment opportunities.

Asset Mix

Pending investment in venture capital trust qualifying securities, surplus cash is primarily held in interest bearing instant access, short-notice bank accounts, money market funds and investment funds listed on a recognised stock exchange (including FCA authorised and regulated UCITS funds). Subsequent to the Finance (No. 2) Act 2015 investments can no longer be made in non-qualifying quoted investments traded on an unregulated exchange. This change therefore now excludes most AIM investments in this category.

Outlook

With most portfolio businesses having come through the pandemic largely unscathed or with improved competitive positions, your Company has been increasingly supporting those that are investing for accelerated growth.

As we come out of the pandemic the volume of opportunities to back innovative business models and management teams continues to be strong. The plans to add additional investment capacity are intended to ensure that your Company remains well funded to take advantage of the investment opportunities as they arise.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

10 September 2021

For further information please contact:

David Hall YFM Private Equity Limited Tel: 0113 244 1000

Alex Collins Panmure Gordon (UK) Limited Tel: 0207 886 2767

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRFEALNEFAFFEFA
Date   Source Headline
3rd Apr 20247:58 amRNSIssue of Equity and Close of Offers
26th Mar 202411:11 amRNSTransaction in Own Shares and Total Voting Rights
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
15th Mar 202412:15 pmRNS3rd Quarter Results
16th Feb 20243:52 pmRNSClose of Offers to New Applications
16th Feb 20243:51 pmRNSClose of Offers to New Applications
30th Jan 20249:23 amRNSIssue of Equity
18th Dec 20234:02 pmRNSTransaction in Own Shares
13th Dec 20234:00 pmRNSOffer Update
13th Dec 20234:00 pmRNSStrategy/Company/Ops Update
8th Dec 20239:47 amRNSPayment of Dividend and Issue of Equity
24th Nov 20237:00 amRNSHalf-year Report
26th Oct 20231:34 pmRNSDividend Declaration
24th Oct 20231:20 pmRNSOffer Update
24th Oct 20231:19 pmRNSOffer Update
6th Oct 202310:19 amRNSOffer Update
6th Oct 202310:17 amRNSOffer Update
27th Sep 20238:21 amRNSOffer Update
26th Sep 20238:20 amRNSTransaction in Own Shares and PDMR
20th Sep 202312:30 pmRNSPublication of a Prospectus
20th Sep 202312:30 pmRNSPublication of a Prospectus
14th Sep 202310:28 amRNSResult of AGM
14th Sep 202310:28 amRNSResult of General Meeting
13th Sep 20237:00 amRNS1st Quarter Results
2nd Aug 202310:25 amRNSNew combined offer for subscription
2nd Aug 202310:25 amRNSNew combined offer for subscription
28th Jul 202310:00 amRNSDirector/PDMR Shareholding
28th Jul 202310:00 amRNSPayment of Dividend and Issue of Equity
27th Jun 20237:45 amRNSTransaction in Own Shares
21st Jun 20231:00 pmRNSPublication of Circular
16th Jun 202312:00 pmRNSAnnual Financial Report
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:23 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:42 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNS3rd Quarter Results
14th Feb 20234:35 pmRNSOffer Update
14th Feb 20234:35 pmRNSOffer Update
11th Jan 202310:00 amRNSDirector/PDMR Shareholding
11th Jan 202310:00 amRNSPayment of Dividend and Issue of Equity
19th Dec 20228:48 amRNSTransaction in Own Shares
6th Dec 20229:58 amRNSOffer Update
6th Dec 20229:58 amRNSOffer Update
30th Nov 202212:30 pmRNSPublication of a Prospectus
30th Nov 202212:30 pmRNSPublication of a Prospectus
25th Nov 20229:30 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.